InMed Pharmaceuticals (INM) Status Update summary

Advances in Alzheimer's disease research

• Alzheimer's is a leading cause of dementia, affecting 6.9M Americans and costing $360B annually.

• Recent years have seen the first disease-modifying therapies launched in several countries, marking a significant milestone after decades of research and failed attempts.

• Removal of amyloid from the brain is now possible, with therapies also impacting tau and inflammatory biomarkers, though clinical benefits vary among individuals.

• Patient selection for clinical trials has improved through biomarker criteria, enhancing efficacy signals and reducing misdiagnosis.

• The field is shifting toward precision medicine, recognizing the heterogeneity of Alzheimer's and the need for individualized approaches.

Neuroinflammation as a therapeutic target

• Chronic neuroinflammation is increasingly recognized as a key contributor to Alzheimer's pathology, with genetic and epidemiological evidence supporting its role.

• New compounds, such as INM-901, show promise in reducing neuroinflammation and promoting neurogenesis in preclinical studies.

• Demonstrates neuroprotective effects, reduced neuroinflammation, and enhanced neuronal function in preclinical studies.

• Neuroinflammation is not a linear process; it varies across brain regions and disease stages, suggesting the need for stage-specific interventions.

• Drug repurposing and combination therapies are emerging strategies to address the complex inflammatory cascades in Alzheimer's.

INM-901 mechanism and preclinical data

• INM-901 is a small molecule drug candidate acting as a preferential agonist for CB1/CB2 and impacting PPAR pathways.

• Promotes neurite outgrowth, supporting cell-to-cell communication essential for brain processing.

• Dose-dependent improvements in cell survival, neurite length, and behavioral outcomes observed in animal models.

• Molecular data show reduced pro-inflammatory gene expression and amyloid plaque levels after treatment.

• Long-term preclinical studies confirm improvements in cognition, memory, and locomotor activity, with statistical significance in some measures.